Compare PG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PG | AZN |
|---|---|---|
| Founded | 1837 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.1B | 286.0B |
| IPO Year | 2015 | 1995 |
| Metric | PG | AZN |
|---|---|---|
| Price | $170.41 | $178.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 12 |
| Target Price | $174.26 | ★ $209.91 |
| AVG Volume (30 Days) | ★ 7.3M | 2.7M |
| Earning Date | 10-22-2026 | 10-30-2026 |
| Dividend Yield | ★ 2.54% | 1.77% |
| EPS Growth | ★ 1.69 | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $87,032,000,000.00 | N/A |
| Revenue This Year | $3.20 | $7.90 |
| Revenue Next Year | $3.16 | $6.38 |
| P/E Ratio | $87.18 | ★ $31.91 |
| Revenue Growth | ★ 3.26 | N/A |
| 52 Week Low | $137.62 | $88.41 |
| 52 Week High | $173.59 | $212.71 |
| Indicator | PG | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 50.82 |
| Support Level | $141.89 | $174.13 |
| Resistance Level | $170.52 | $193.52 |
| Average True Range (ATR) | 2.91 | 3.55 |
| MACD | 0.16 | -1.06 |
| Stochastic Oscillator | 73.13 | 0.75 |
Since its founding in 1837, Procter & Gamble has become one of the world's largest consumer product manufacturers, with annual sales of more than $87 billion. It operates with a lineup of leading brands, including more than 20 that generate annual global sales of more than $1 billion each, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside the US represent just over half of the firm's consolidated total.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.